A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids
Latest Information Update: 17 Sep 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Nasal congestion; Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Acronyms SINUS-52
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 13 Sep 2024 According to Regeneron Pharmaceuticals media release,company announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)
- 01 Dec 2023 Results of pooled analysis (n=688 from NCT02912468 and NCT02898454) assessing the relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP published in the Rhinology
- 18 May 2022 Results of (SYNAPSE [mepolizumab], SINUS 24/52 [dupilumab], POLYP 1/2 [omalizumab]) assessing the feasibility of conducting an ITC to obtain unbiased estimates of the relative efficacy of biologics for treatment of uncontrolled chronic rhinosinusitis with nasal polyps, presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.